The lights have dimmed at one of the brightest stars in UK biotech as the artificial intelligence specialist Exscientia plc faces up to the fallout from the sacking of founder and CEO Andrew Hopkins over “inappropriate” relationships with two members of staff.
Shares in the NASDAQ-listed Oxford-based group slumped nearly 23% to $5.80 on 13 February after Exscientia revealed in a US...





